Antagonist

Results: 956



#Item
611system. Smoking-induced reduction in skin blood flow also can be antagonized by a vascular vasopressin antagonist, which suggests a role for vasopressin in mediating some cardiovascular responses (2). The cardiovascular

system. Smoking-induced reduction in skin blood flow also can be antagonized by a vascular vasopressin antagonist, which suggests a role for vasopressin in mediating some cardiovascular responses (2). The cardiovascular

Add to Reading List

Source URL: profiles.nlm.nih.gov

Language: English - Date: 2001-09-25 16:07:08
612B.C. Ministry of Health Services Drug Coverage Decisions About PharmaCare PharmaCare Coverage  Inside

B.C. Ministry of Health Services Drug Coverage Decisions About PharmaCare PharmaCare Coverage Inside

Add to Reading List

Source URL: www.health.gov.bc.ca

Language: English - Date: 2014-03-05 12:02:53
613Microsoft Word - Hershberger_phase-3[PRP].doc

Microsoft Word - Hershberger_phase-3[PRP].doc

Add to Reading List

Source URL: epa.gov

Language: English - Date: 2008-03-24 10:32:24
614AR Binding Assay Fact Sheet

AR Binding Assay Fact Sheet

Add to Reading List

Source URL: www.epa.gov

Language: English - Date: 2008-03-24 10:32:06
615levatol® tablets (penbutolol sulfate) 20 mg Rx Only DESCRIPTION

levatol® tablets (penbutolol sulfate) 20 mg Rx Only DESCRIPTION

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-05-05 14:18:21
616Peer Review Panel Comments on the AR Binding Assay

Peer Review Panel Comments on the AR Binding Assay

Add to Reading List

Source URL: epa.gov

Language: English - Date: 2008-03-24 10:32:06
617Draft Report on the Current Status of Test Methods for Detecting Endocrine Disruptors: In Vitro Estrogen Receptor Transcriptional Activation Assays - April 2002

Draft Report on the Current Status of Test Methods for Detecting Endocrine Disruptors: In Vitro Estrogen Receptor Transcriptional Activation Assays - April 2002

Add to Reading List

Source URL: www.epa.gov

Language: English - Date: 2007-11-01 13:24:47
618HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZUPLENZ® safely and effectively. See full prescribing information for ZUPLENZ. ZUPLENZ (ondansetron) Oral Soluble F

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZUPLENZ® safely and effectively. See full prescribing information for ZUPLENZ. ZUPLENZ (ondansetron) Oral Soluble F

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-10-31 17:25:06
619Zebeta® (Bisoprolol Fumarate) Tablets November[removed][removed]Rx only

Zebeta® (Bisoprolol Fumarate) Tablets November[removed][removed]Rx only

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-02-04 14:55:20
620HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYTRIL safely and effectively. See full prescribing information for KYTRIL.  •

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYTRIL safely and effectively. See full prescribing information for KYTRIL. •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-05-02 15:57:58